CSL

News

CSL, BrightInsight launch Hemgenix companion app

CSL Behring's recently approved gene therapy for haemophilia B Hemgenix has joined the swelling ranks of new medicines that are bundled with a companion app to support the

Market Access

CSL opens a new R&D facility in Waltham, Massachusetts

On March 27th, global biopharma company CSL opened a new R&D facility in Waltham, Massachusetts.

R&D

CSL reflects on its future, past as new R&D lab opens

Last month, global pharmaceutical maker CSL cut the ribbon on a brand-new research facility in Waltham, Massachusetts, wher

News

Phase 3 trial win sets up rare disease drug filing for CSL

VANUGUARD trial of garadacimab in HAE sets up a pursuit of Takeda's fast-growing Takhyzro.

News

CSL’s Hemgenix is first haemophilia B gene therapy in EU

Firm will work with payers to try to secure access for as many patients across EU as possible.

News

CSL closes on EU approval for haemophilia B gene therapy

CSL's gene therapy for haemophilia B has been recommended for approval by the EMA's human medicine committee, setting up a decision by the European Commission early next year.

CSL, BrightInsight launch Hemgenix companion app

CSL opens a new R&D facility in Waltham, Massachusetts

CSL reflects on its future, past as new R&D lab opens

Phase 3 trial win sets up rare disease drug filing for CSL

CSL’s Hemgenix is first haemophilia B gene therapy in EU

CSL closes on EU approval for haemophilia B gene therapy

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

CSL

Editor's Picks